When Medications Backfire: A Case Report of Rifaximin-Induced Rhabdomyolysis in a Kidney Transplant Patient
Munsef Barakat, Salem Vilayet, Genta Uehara, Abubakr Adala, Ahmed I Kamal, Karim Soliman
TL;DR
A kidney transplant patient developed severe muscle damage from the medication rifampicin, complicated by a rejection of the transplanted kidney.
Contribution
This case report highlights rifampicin as a rare cause of rhabdomyolysis in kidney transplant recipients.
Findings
Rifampicin-induced rhabdomyolysis occurred in a kidney transplant patient.
The patient also experienced acute cellular rejection, complicating the clinical picture.
Abstract
Rhabdomyolysis involves significant skeletal muscle injury and destruction, which can be triggered by trauma, intense physical activity, heat, prolonged immobility, certain medications, and endocrine disorders. Rhabdomyolysis in renal transplants can be more complicated, and the prognosis is not well known, especially in the context of coexisting rejection. We present a case of rifampicin-induced rhabdomyolysis with superimposed acute cellular rejection in a kidney transplant patient.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMuscle and Compartmental Disorders · Myeloproliferative Neoplasms: Diagnosis and Treatment · Eosinophilic Disorders and Syndromes